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Article: 
One of the biggest challenges in economic development is the reality that magic bullets are rare. As a rule, the 
best policy lays foundations and invests in infrastructure. And that isn’t very sexy, is it? 
 
That’s why it’s important to act decisively when an economic opportunity comes along. When President Bush 
vetoed a key funding bill for stem-cell research last month, he created an opening for the states to step in and fill 
the gap created by the federal government. North Carolina should jump at this opportunity and pass a funding 
bill for stem-cell research in the state. Other states may do the same, so time’s a-wastin’. 
 
The bill vetoed by the president would have expanded federal funding for human embryonic stem-cell research. 
Among other things, the bill would have generated new stem-cell lines from embryos originally created for 
research and treatment and donated by patients. Even though those cells will never be implanted to grow into 
human beings, opponents of stem-cell research argue that gathering embryonic material in this way is murder. 
 
Proponents point to the tremendous medical potential of therapies derived from stem-cell research. Stem cells 
have the ability to be used as a repair system for the body, and stem-cell research could help doctors repair 
tissue or grow organs. Stem-cell therapies could eventually treat cancer and neurological disorders. But for the 
most part, these wonders lie in the future and will never be discovered unless we invest in stem-cell research. 
 
I’ll leave the ethics of stem-cell research to others, in particular our legislators in Raleigh. According to the 
News & Record, State Rep. Earl Jones of Greensboro has advocated greater state investment in SCR, and 
perhaps because of his efforts a legislative committee will study the merits of introducing a $20 million stem-
cell research bill in the coming year. There could be additional costs, however. California allocated $3 billion in 
state money to SCR in 2004, but the money has been tied up in court ever since due to intellectual-property 
suits. Court costs don’t grow on trees. Even so, let’s hope the state opts for some level of new funding. 
 
Stem-cell research is a good fit for North Carolina’s growing biotechnology sector. There is an infrastructure of 
biotech companies and research programs throughout the state. Unlike so many government programs that 
throw money at flavor-of-the-month industries, money spent on biotech in North Carolina is a seed that has a 
very good chance of bearing fruit in the future. 
 
In 2005, more than 35,000 people were employed by North Carolina’s biotechnology sector, accounting for 1.1 
percent of all private employment in the state. And that number doesn’t include those on government and 
college payrolls. Only seven states had more private-sector biotech employees than North Carolina, and only 
three of those seven exhibited a greater degree of specialization in biotechnology. For example, California’s 
massive biotech sector of 138,000 employees is actually slightly smaller than North Carolina’s when each is 
compared to its entire state economy. 
 
According to the accounting and consulting firm Ernst & Young, in 2005 only two states, California and 
Massachusetts, were home to more biotechnology companies than North Carolina. A study by the Milken 
Institute showed that of the leading biotechnology states, North Carolina has the lowest cost of doing business. 
Biotechnology’s corporate presence in North Carolina is buttressed by the state’s universities and community 
colleges. Biotech research funding at North Carolina universities totals approximately $1.6 billion annually, and 
about half of the state’s new doctorate recipients do their work in biology and related life sciences. The 
community college system’s BioNetwork is a nationally recognized program that trains the biotech workforce 
of the future. 
 
In a study last year by UNCG’s Office of Business and Economic Research, geographer Keith Debbage found 
that roughly two-thirds of all biotech jobs in the state are located in the three major metropolitan areas of the 
Research Triangle, the Triad, and Charlotte. Over half are located in the Triangle alone. However, Debbage 
believes there are opportunities for the Triad to leverage its proximity to the Triangle in various subfields, 
including the Triad’s already strong drug-manufacturing industry. 
 
Debbage also found that earnings in the Triad biotech sector, an indicator of a skilled workforce, are relatively 
high. This is consistent with another OBER study conducted this summer by UNCG economist Don Jud, which 
surveyed a panel of Triad biotech executives who reported being generally happy with the region’s business 
climate and availability of skilled workers. 
 
Therefore, it appears that North Carolina and the Triad are in an excellent position to capitalize on the federal 
government’s reluctance to fund stem-cell research. In a perfect world, it might be better for stem-cell research 
to be funded at the federal level, but that’s not going to happen in the near future. Already, a number of states, 
led by both Republican and Democratic governors, have reacted to the Bush veto by announcing plans to 
increase funding of stem-cell research in their states. Let’s hope that North Carolina doesn’t miss its chance to 
jump through this window of opportunity. 
